医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Toyoda Gosei Develops UV-C LED with World-Class Light Output

2024年04月22日 PM05:58
このエントリーをはてなブックマークに追加


 

KIYOSU, Japan

Toyoda Gosei Co., Ltd. (TOKYO:7282) has developed deep ultraviolet (UV-C) LEDs with light output that is among the highest in the world.1 UV-C is used in disinfection as it destroys viral and bacterial DNA structures and inhibits their replication. As an alternative light source for mercury lamps used for disinfection, improved performance of UV-C LEDs has been expected. Sample sales of Toyoda Gosei’s high power LEDs will begin internationally from April 2024,2 to promote their wider use for disinfecting water, air and surface.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240411192378/en/

High power UV-C LED (Graphic: Business Wire)

High power UV-C LED (Graphic: Business Wire)

Compared with mercury lamps, UV-C LEDs are environmentally-friendly as it is mercury-free, more compact, and have a longer life. These advantages promoted their wide use in devices for disinfecting air and surfaces during the Covid-19 pandemic. Since they differ from lighting LEDs in composition, however, light output has been still limited. For water purification plants and other situations where high disinfection performance is needed, mercury lamps are still used.

Toyoda Gosei has leveraged its expertise in crystallization and design of blue LEDs for lighting, and successfully developed UV-C LEDs that achieve light output at the level of 200 milliwatts with a single chip when driven by a current of 350 milliamperes. Improvement of the LED structure and composition quadrupled the amount of light that can be extracted. Enhanced LED performance including disinfecting capability of about three times higher will expand their applicable areas including a future alternative to mercury lamps, contributing to more hygienic and safer living.

1

As of March 31, 2024. Toyoda Gosei survey

2

Sample sales start in Japan, China, and South Korea in April 2024.

Successive starts are planned for other regions.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240411192378/en/

CONTACT

Toyoda Gosei Co., Ltd.

Contact: Life Solution Sales Dept.

+81-52-449-5717

https://www.toyodagosei-led.jp/en/form/

同じカテゴリーの記事 

  • Heuron Gets FDA Green Light for Stroke Triage and Notification Solution
  • iCell Gene Therapeutics Announces Positive Clinical Data from Investigator Initiated Phase 1 Trial Evaluating BCMA-CD19 Compound CAR in Patients with Systemic Lupus Erythematosus/Lupus Nephritis Published in Annals of the Rheumatic Diseases
  • Galderma Launches Restylane® VOLYME™ in China – One of the World’s Fastest Growing Aesthetics Markets
  • Immunis Partners with Japanese Drug Company Toray to Reverse Sarcopenia
  • Otsuka to Terminate Development of AVP-786